Atossa Therapeutics, Inc. Common Stock
ATOSAtossa Therapeutics, Inc. (ATOS) is a biotechnology company focused on developing targeted treatments for breast cancer, hormone-related issues, and other serious medical conditions. The company is particularly known for its research into novel therapies involving breast health and hormone modulation, aiming to address unmet medical needs through innovative drug delivery methods and clinical development efforts.
Company News
Atossa Therapeutics' CEO Dr. Steven Quay will participate in a fireside chat at the 27th Annual H.C. Wainwright Global Investment Conference, discussing clinical progress of their lead product (Z)-endoxifen, a potential breast cancer treatment and prevention therapy.
Atossa Therapeutics, a clinical-stage biopharmaceutical company, announced that its Vice President of Investor and Public Relations will participate in a virtual fireside chat at the 2024 Maxim Healthcare Virtual Summit.
SEATTLE, June 28, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced protocol changes in the previously initiated study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib (VERZENIO®), a cyclin-dependent kinase (CDK) 4/6 inhibitor marketed by Eli Li...
Here is how Alvotech (ALVO) and Atossa Genetics Inc. (ATOS) have performed compared to their sector so far this year.
SEATTLE, June 17, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced its expected upcoming inclusion in the Russell 3000® Index, according to preliminary Russell reconstruction information posted on the FTSE Russell website. The newly reconstructed index will take effect after...
